DigiFab (Digibind) Dosing for Digoxin Poisoning
ورودیهای بالینی بیمار
حداقل ۰.۵ — حداکثر ۶۲۰ • واحد: kg
حداقل ۰ — حداکثر ۱۰۰ • واحد: ng/mL
حداقل ۰ — حداکثر ۱۰۰ • واحد: mg
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low dose1–2
- Moderate dose3–6
- High dose7–10
- Very high dose11–20
The DigiFab (Digibind) Dosing for Digoxin Poisoning calculates assessing acute poisoning severity, antidote indications, and fatal toxicity trajectory. Key inputs include method. Scores guide administering specific antidote therapy, gastrointestinal decontamination, and continuous telemetry monitoring. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Doses DigiFab in patients with confirmed digoxin poisoning or overdose
Clinical Indication
The DigiFab (Digibind) Dosing for Digoxin Poisoning is indicated for bedside clinical practice to support Doses DigiFab in patients with confirmed digoxin poisoning or overdose. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with acute pharmaceutical overdose, agricultural pesticide ingestion, toxic gas inhalation, or venomous envenomation. Clinical application is indicated across Poison control centers, acute toxicology wards, emergency resuscitation rooms, and intensive care.
Limitations & Contraindications
Initial serum concentrations for sustained-release or co-ingested anticholinergic agents may falsely appear low before delayed absorption peaks.
Clinical Pearls & Action Plan
Rapid clinical toxidrome identification guides immediate antidote administration; do not wait for confirmatory toxicology assays.
For serum level method: Number of vials = (serum digoxin level [ng/mL] × patient weight [kg]) / 100. For amount ingested method: Number of vials = (amount ingested [mg] / 0.5 mg/vial) × 0.8 (80% bioavailability). Always round up to the next whole number.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| method | string | Yes | Calculation method to use |
| weight_kg | float | No | Patient body weight in kilograms (required for serum level method)(kg) |
| serum_digoxin_level | float | No | Serum digoxin level in ng/mL (required for serum level method)(ng/mL) |
| amount_ingested_mg | float | No | Total amount of digoxin ingested in mg (required for amount ingested method)(mg) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 1–2 | Low dose | Low dose requirement |
| 3–6 | Moderate dose | Moderate dose requirement |
| 7–10 | High dose | High dose requirement |
| 11–20 | Very high dose | Very high dose requirement |
| 21–999 | Extreme dose | Extreme dose requirement |
Evidence-Based References (EBM)
- Lapostolle F, Borron SW, Verdier C, et al. Digoxin-specific Fab fragments as single first-line therapy in digitalis poisoning. Crit Care Med. 2008;36(11):3014-8.
- Antman EM, Wenger TL, Butler VP Jr, Haber E, Smith TW. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation. 1990;81(6):1744-52.
- Bismuth C, Gaultier M, Conso F, Efthymiou ML. Hyperkalemia in acute digitalis poisoning: prognostic significance and therapeutic implications. Clin Toxicol. 1973;6(2):153-62.